Sight Sciences Q4 interventional dry eye revenue rises 133% to $0.7M
Sight Sciences reported Q4 2025 revenue growth in interventional glaucoma and interventional dry eye segments while emphasizing operating expense discipline and cash management. The company secured Medicare pricing for CPT code 0563T and saw interventional dry eye revenue climb to $0.7 million from $0.3 million year-over-year.
1. Q4 2025 Financial Results
Sight Sciences delivered sequential and year-over-year growth in both its interventional glaucoma and interventional dry eye segments, driven by SmartLids sales to approximately 80 accounts and strong customer engagement in key regions. Management highlighted continued operating expense discipline and proactive cash management throughout the period.
2. Strategic Shift to Interventional Focus
The company reframed its business segments from surgical glaucoma and dry eye to interventional glaucoma and interventional dry eye, reflecting a focus on earlier, procedure-based interventions to improve standards of care and drive cross-segment synergies.
3. Reimbursement Milestone and Commercial Traction
In Q4, Medicare Administrative Contractors established pricing for CPT code 0563T tied to the TearCare procedure, marking a pivotal reimbursement milestone. Interventional dry eye revenue increased to $0.7 million from $0.3 million, supported by sales of roughly 700 SmartLids and 30 new account engagements.
4. 2026 Guidance and Operational Discipline
Leadership initiated 2026 revenue and adjusted operating expense guidance, reiterating a strategy to return to double-digit growth while maintaining operational rigor and financial discipline to support sustainable expansion.